Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Bausch Health

Bausch Health Adds Late-Stage Ready Alcohol Liver Disease Drug Candidate In $63 Million DURECT Buyout

Bausch Health Companies Inc. (NYSE:BHC) on Tuesday agreed to indirectly acquire DURECT Corp (NASDAQ:DRRX), including a novel therapeutic molecule, larsucosterol.

8 Brand Names That Changed to Hide a Bad Reputation

Changing a brand name is a big move. Companies do it when their old name starts to hurt their business. Sometimes, a brand becomes associated with scandals, lawsuits, or unfavorable press. When that happens, a new name can help them start fresh. For shoppers, these changes can be confusing. You…

Grocery Coupon Guide

Bausch Reportedly Explores A Sale; Could Alcon, J&J Or AbbVie Buy It?

Bausch Reportedly Explores A Sale; Could Alcon, J&J Or AbbVie Buy It?

Bausch + Lomb stock surged Monday — briefly breaking out — on a report the company is working with advisors to explore a potential sale.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

This Bausch Health Companies Unusually Active Option Is a No-Brainer

Bausch Health Companies had the 8th-highest Vol/OI ratio in Wednesday trading. The pharmaceutical company’s unusual options activity suggests it might have more gains ahead.

Daily Biotech Pulse: Bausch Health To Appeal Xifaxan Patent Decision, Bristol Myers Drug Combo Fails In Kidney Cancer Trial, Sarepta's Duchenne Candidate Update

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga Before The Bell: Apple's Strong China Revenue, Amazon's EV Partnership, Jack Ma To Cede Control Of Ant Financial And Other Top Financial Stories Friday, July 29

Reuters Tencent’s Overseas Ambitions Face Resistance From India

Bausch Health's Q1 Sales, Profits Fall On Supply Chain Challenges, Cuts FY22 Outlook

Bausch Health Companies Inc (NYSE:BHC) has reported Q1 revenues of $1.92 billion, down 5% Y/Y. Excluding the unfavorable impact of foreign exchange of $41 million and divestitures & discontinuations of $72 million, revenue was flat organically compared to Q1 FY21. Adjusted net income declined to $263 million from $370 million a year…

inkl

Read news from The Economist, FT, and more,
with one subscription

Bausch Health Crashes On Unexpected Loss As Bausch & Lomb Starts Trading

Bausch Health Crashes On Unexpected Loss As Bausch & Lomb Starts Trading

Bausch Health Companies reported an unexpected first-quarter loss and light sales on Tuesday and BHC stock crashed.

Investors Business Daily

Bausch Health Companies Q4 Sales, FY22 Outlook Lag Wall Street View

Bausch Health Companies Q4 Sales, FY22 Outlook Lag Wall Street View

Bausch Health Companies Inc (NYSE: BHC) has reported

People

Mark Zuckerberg

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Wall Street Journal

Amazon.com Inc.

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

290,709 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play